BioHarvest Sciences Inc. has announced a new contract through its Botanical Synthesis CDMO Services division to develop a plant-based fragrance compound. The agreement, which includes milestone-based payments and a non-disclosure agreement for Stage 1, expands BioHarvest's platform into the fragrance market. Utilizing its advanced AI-assisted research capabilities, the company identified specific plant species to develop a cell bank for efficient production of fragrance molecules. Stage 1 will use BioHarvest's proprietary Botanical Synthesis platform to replicate and multiply the plant's targeted cells. A successful outcome could lead to Stage 2, involving production in liquid media, paving the way for future manufacturing. CEO Ilan Sobel highlighted the contract as validation of the platform's ability to deliver scalable solutions while conserving threatened plant species.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。